Consolidated Statements of Equity - USD ($) shares in Thousands, $ in Thousands	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2019			10	10,529
Beginning Balance at Dec. 31, 2019	$ 20,553	$ 20,816	$ 0	$ 11	$ 438,911	$ 2	$ (417,400)	$ (708)	$ (263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(2,709)	(2,719)					(2,719)		10
Unrealized loss on marketable securities	(14)	(14)				(14)
Share-based compensation (in shares)				81
Share-based compensation	942	942			942
Net proceeds from issuance of common stock and warrants (in shares)				8,797
Net proceeds from issuances of common stock and warrants	18,715	18,715		$ 8	18,707
Ending Balance (shares) at Sep. 30, 2020			10	19,407
Ending Balance at Sep. 30, 2020	37,487	37,740	$ 0	$ 19	458,560	(12)	(420,119)	(708)	(253)
Beginning Balance (shares) at Jun. 30, 2020			10	15,585
Beginning Balance at Jun. 30, 2020	33,556	33,811	$ 0	$ 16	449,302	(7)	(414,792)	(708)	(255)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(5,325)	(5,327)					(5,327)		2
Unrealized loss on marketable securities	(5)	(5)				(5)
Share-based compensation (in shares)				(25)
Share-based compensation	229	229			229
Net proceeds from issuance of common stock and warrants (in shares)				3,847
Net proceeds from issuances of common stock and warrants	9,032	9,032		$ 3	9,029
Ending Balance (shares) at Sep. 30, 2020			10	19,407
Ending Balance at Sep. 30, 2020	37,487	37,740	$ 0	$ 19	458,560	(12)	(420,119)	(708)	(253)
Beginning Balance (shares) at Dec. 31, 2020			10	19,389
Beginning Balance at Dec. 31, 2020	32,242	32,496	$ 0	$ 19	458,748	(13)	(425,550)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(20,672)	(20,672)					(20,672)		0
Unrealized loss on marketable securities	(51)	(51)				(51)
Share-based compensation (in shares)				535
Share-based compensation	1,391	1,391			1,391
Net proceeds from issuance of common stock and warrants (in shares)				39,860
Net proceeds from issuances of common stock and warrants	85,479	85,479		$ 41	85,438
Proceeds from option exercises (in shares)				7
Proceeds from option exercises	24	24			24
Ending Balance (shares) at Sep. 30, 2021			10	59,791
Ending Balance at Sep. 30, 2021	98,413	98,667	$ 0	$ 60	545,601	(64)	(446,222)	(708)	(254)
Beginning Balance (shares) at Jun. 30, 2021			10	59,529
Beginning Balance at Jun. 30, 2021	104,679	104,933	$ 0	$ 60	544,893	(17)	(439,295)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(6,927)	(6,927)					(6,927)		0
Unrealized loss on marketable securities	(47)	(47)				(47)
Share-based compensation (in shares)				262
Share-based compensation	708	708			708
Ending Balance (shares) at Sep. 30, 2021			10	59,791
Ending Balance at Sep. 30, 2021	$ 98,413	$ 98,667	$ 0	$ 60	$ 545,601	$ (64)	$ (446,222)	$ (708)	$ (254)